FountainVest Partners and Primavera Capital have paid $557 million for a 24.78% stake in Chinese pharmacy chain Laobaixing. It will provide a full exit for EQT Partners.
The two investors will each take approximately 12.4% shares via FountainVest China Capital Partners Fund III and Primavera Capital Fund III, according to a statement. EQT Partners became the second-largest...
Warburg Pincus will sell an approximately 5.5% interest in Hong Kong-listed IVF services provider Jinxin Fertility for about HK$1.5 billion ($194 million) through a share placement.
CLSA, the international arm of China-based brokerage CITIC Securities, has launched a strategy to offer high net worth clients investment opportunities in late-stage private companies in Asia.
DCM Ventures has raised $880 million across two funds that will continue its early-stage technology strategy, with 70% of the capital earmarked for deployment in China.
Having previously focused on offshore IPOs, China managers with US dollar funds are now considering the Star Market. But going onshore means more regulation as well as high valuations